ImmuCell Corp. Hits New 52-Week High of $10.65, Up 145%

ImmuCell Corp., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 10.65 on May 26, 2026. This achievement marks a remarkable increase of 145.04% over the past year, significantly outperforming the S&P 500, which has seen a gain of 29.58% during the same period. With a market capitalization of USD 58 million, ImmuCell Corp. operates with a price-to-earnings (P/E) ratio of 25.00, indicating its valuation relative to earnings. The company maintains a low debt-to-equity ratio of 0.19, reflecting a conservative approach to leverage. Additionally, ImmuCell's return on equity stands at 7.80%, showcasing its efficiency in generating profits from shareholders' equity. The stock's previous 52-week low was recorded at USD 4.52, highlighting the substantial growth it has experienced in the past year. As ImmuCell Corp. continues to navigate the dynamic landscape of the pharmaceuticals and biotechnology industry, this new high underscores its current market position and performance metrics.